Abstract: The global population is increasingly ageing, necessitating the development of therapeutic strategies for ageing-related diseases. Sarcopenia, characterised by low muscle strength, low muscle mass, and diminished physical performance, poses a significant risk of falls, loss of autonomy, and increased dependency in the elderly. Systemic immune-inflammation has been implicated in the pathophysiology of sarcopenia, underscoring the need for targeted therapies. Mesenchymal stromal cells (MSCs) have emerged as a promising option due to their potent immunomodulatory properties, which may address both muscle degeneration and associated inflammatory responses.
Traditional models for studying sarcopenia, such as hindlimb unloading, immobilisation, and denervation, often fail to accurately replicate the complex, multifactorial nature of the condition in humans. This limitation complicates the translation of preclinical findings to clinical practice. Our study utilised naturally aged mice as a more relevant model to investigate the efficacy of systemic MSC therapy in treating sarcopenia and other age-related symptoms.
Our findings indicate that MSC treatment significantly improves muscle function and muscle mass in an age-induced sarcopenia mouse model. Notably, MSC-treated mice exhibited reduced systemic inflammation levels, suggesting a potential link between MSC therapy and immunomodulation. Furthermore, therapeutic benefits persisted for several months post-treatment cessation, indicating long-lasting effects on muscle function and quality. These enduring improvements may be attributed to sustained changes in the inflammatory environment and enhanced muscle repair mechanisms initiated by MSC therapy.
This study provides robust support for the continued clinical application of MSC therapy for sarcopenia, aiming to enhance the quality of life for the elderly.
Funding Source: This work was supported by Center for Neuromusculoskeletal Restorative Medicine (Ref. No. CT1.1), Health@InnoHK program, Innovation Technology Commission, Hong Kong SAR, China.
